The Pharmacology Core's mission is to provide state-of-the-art bioanalytic technology and a broad range of pharmacology expertise to enable evaluation of critical pharmacological endpoints in clinical trials and preclinical studies. The Pharmacology Core is grouped in the Cross Disciplinary Research Core Cluster which, in addition to the Pharmacology Core, includes the Biostatistics, Genomics, and the Biobanking and Correlative Sciences Cores. Two services, Biospecimen Processing and Bioanalysis, are provided on a fee-for-service basis. Biospecimen Processing is a centralized resource for the acquisition, processing, and shipment of patient specimens (including blood and bone marrow samples) that are required for evaluation of pharmacokinetics or pharmacodynamics according to clinical protocol specifications to facilitate and support clinical and laboratory research. Bioanalysis provides development, validation and implementation of high-performance liquid chromatography (HPLC)-based analytical methods for quantitative measurement of drugs, metabolites, or endogenous compounds in biological samples (including biofluid, tissue and cell culture samples). In addition, a broad range of pharmacology support is provided, including: 1) pharmacokinetic study design; 2) pharmacokinetic data analysis and modeling using traditional compartmental and non-compartmental analysis, nonlinear mixed-effect (population) pharmacokinetic modeling, and physiologically based pharmacokinetic modeling; 3) in vitro drug metabolism studies; 4) metabolite identification; and 5) determination of drug plasma protein binding and plasma-to-blood ratio. The Core is equipped with state-of-the-art analytical instruments (such as the AB SCIEX QTRAP 6500 LC- MS/MS system) and pharmacokinetic analysis software. The laboratory is centrally located with convenient access for all KCI investigators. The services provided by the Pharmacology Core have contributed to 92 peer-reviewed publications during the current review period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-38
Application #
9836639
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
38
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017

Showing the most recent 10 out of 826 publications